What are the cognitive benefits of using Semax?
Semax improves learning speed, memory consolidation, selective attention, and working memory. Evidence for these effects comes from both animal and clinical studies in humans. Semax's pro-cognitive action has a solid biological basis. This peptide increases levels of BDNF and NGF – proteins essential for nerve cell growth and survival, enhances hippocampal synaptic plasticity, modulates key neurotransmitter systems including cholinergic and dopaminergic ones, and activates intracellular signalling cascades underlying memory formation and consolidation. These effects have been observed in numerous animal models and – to a limited extent – in humans, over several decades of research primarily conducted by Russian scientific institutions.
Does Semax improve memory?
Semax improves memory consolidation and retention in many experimental models. Evidence from animal studies is consistent, and clinical data from human trials add significant value that translates into medical practice.
In the passive avoidance test — one of the most commonly used animal fear-based memory tests, where animals learn to avoid a place associated with a mild electric shock — intranasal Semax significantly improved both memory acquisition and consolidation in rats. The intranasal route also proved more effective than intraperitoneal injection at equivalent doses [1], consistent with better delivery of the peptide to the brain via the nasal pathway.
In rats with experimentally induced ischaemic damage to the prefrontal cortex (using the photothrombotic technique), chronic intranasal administration of Semax at a dose of 250 micrograms per kilogram of body weight per day for six days fully restored spatial learning ability in the Morris water maze. This is a standard memory test where animals must use environmental cues to find a hidden platform in a pool of water. Importantly, the memory-restoring effect persisted long after treatment cessation, suggesting that Semax induced lasting changes in brain circuitry rather than mere short-term pharmacological support [2]. In a similar model of cortical stroke, intranasal Semax for six days reduced lesion volume and improved both the consolidation and performance of conditional memory responses [3].
Semax also protects against pharmacologically induced amnesia. In studies on rats subjected to carotid artery blockage combined with extreme physical stress, it prevented retrograde amnesia – the loss of previously formed memories – and prolonged the animals' survival time during hypoxia challenges [4]. It also proved effective against amnesia induced by scopolamine, maximal electroshock, and other extreme stress conditions [5].
In healthy volunteers, a review of a 15-year study period noted improvements in working memory following intranasal Semax at doses of 0.015–0.050 mg/kg, with effects lasting for 20–24 hours after a single administration [6].
Does Semax improve concentration and attention?
Semax improves selective attention and concentration, although evidence comes primarily from behavioural animal studies. Data regarding attention in healthy humans outside of clinical populations are limited. A summary of 15 years of research listed improved selective attention—the ability to focus on salient information while filtering out distracters—as one of the two main cognitive domains where Semax has demonstrated efficacy in both rodents and humans [6].
In behavioural studies using an active avoidance test, Semax at a dose of 0.05 mg/kg accelerated the learning rate of avoidance reactions in rats and helped to restore it after disruption by acute environmental manipulation [7]. These results were interpreted as reflecting an improvement in attentional processing and learning efficiency, rather than merely altered fear responses.
In healthy volunteers, a study using resting functional MRI found that Semax expanded the activity of the medial prefrontal cortex—a key region of the default mode network involved in internally directed thought and working memory—both 5 and 20 minutes after administration [8].
Semax also enhances the dopaminergic system's response to stimulation without causing dopamine release on its own [9]. Dopaminergic signalling in the prefrontal cortex plays a crucial role in sustained attention and executive functions—a set of mental abilities including planning, decision-making, and self-regulation. Based on this, it has been hypothesised that Semax may have therapeutic potential in ADHD [10]. However, this has not been investigated in formal clinical trials, and no human studies have yet directly measured the impact of Semax on attentional outcomes using standardised neuropsychological tests in healthy individuals.
Does Semax help with brain fog?
No published clinical studies have investigated Semax specifically as a treatment for brain fog. However, its documented mechanisms of action are directly related to the cognitive impairment, mental fatigue, and slowed information processing that characterise this condition.
BDNF increases support brain cell health and connectivity. Anti-inflammatory gene expression modulation reduces low-grade brain inflammation, increasingly recognised as a key driver of cognitive decline. Enhanced cholinergic function supports memory and attention, and serotonergic activation improves mood and mental energy. Each of these mechanisms targets something that fails in brain fog.
In patients with cerebrovascular insufficiency, a condition where blood flow to the brain is chronically restricted, causing symptoms that significantly overlap with brain fog, a clinical trial of 187 patients showed that Semax treatment resulted in significant clinical improvement, stabilisation of disease progression, and a reduced risk of stroke and transient ischaemic attacks. Neurological and neuropsychological assessments confirmed cognitive benefit [11].
The immunomodulatory and anti-neuroinflammatory properties of Semax — including the suppression of pro-inflammatory proteins IL-1β, IL-6, and TNF-α [12] — relate to one of the proposed primary biological mechanisms driving brain fog in various clinical conditions. However, the direct transference of these findings to brain fog in healthy individuals requires significant extrapolation beyond the current evidence base, which must be clearly stated.
Does Semax support learning?
Semax has a profile of action consistent with supporting cognitive demands related to learning—in particular, learning speed, memory consolidation, and attention. However, no controlled studies have evaluated its effect on academic performance in healthy students.
Behavioural improvements documented in animal learning tests, increased BDNF in hippocampal circuits crucial for memory formation, and enhanced glutamatergic synaptic transmission — where glutamate is the main molecule involved in encoding new memories — collectively suggest a pharmacological basis for cognitive support pertinent to learning.
In the chronic unpredictable stress model, Semax reversed stress-induced anhedonia and restored hippocampal BDNF levels that were reduced by chronic stress [13]. This suggests that it may also protect cognitive performance under the psychological stress conditions often associated with academic demands.
BDNF data indicates that the effect of Semax is most pronounced in individuals with initially low cognitive scores [14]. Benefits may therefore be more noticeable in individuals with stress- or illness-related deficits than in well-functioning healthy individuals. The use of Semax as a learning aid by healthy individuals is an off-label use of an investigational compound with no established safety data in this population, which should be clearly stated.
What are users reporting regarding the cognitive effects of Semax?
User experiences with Semax go beyond the scope of peer-reviewed scientific literature and cannot be assessed with the same rigour as data from controlled clinical trials.
In online nootropic communities, descriptions of improved concentration, verbal fluency, information processing speed, and mood after intranasal administration of Semax often appear. However, these reports are subject to significant confounding factors – placebo effects, variable product quality, inconsistent dosing, and reporting bias. A forensic study analysing seized preparations containing Semax and Selank confirmed their widespread availability as research peptides sold online in many countries [15] – however, availability and popularity do not constitute proof of efficacy.
Anecdotal evidence should be clearly distinguished from controlled clinical evidence.
Does Semax improve cognitive function in clinical populations?
Semax improves mental performance and functional outcomes in patients with neurological conditions. The strongest evidence from human studies comes from trials in stroke and cerebrovascular disease.
In 30 patients with acute ischaemic stroke receiving Semax as part of intensive combination therapy, the rate of recovery of neurological function was accelerated. The most effective daily doses were 12 mg for moderate strokes and 18 mg for severe strokes, administered in 5–10-day courses [16]. EEG and somatosensory evoked potentials monitoring confirmed objective neurophysiological improvements alongside clinical improvements in neurological outcomes [16].
In a study of 110 stroke patients, Semax accelerated improvements in Barthel Index scores—a standard measure of the ability to perform daily activities independently—with these improvements being directly correlated with elevated plasma BDNF levels [17].
In patients with motor neurone disease, Semax did not alter the progression of the disease or electromyographic markers of degeneration, but it significantly improved overall quality of life outcomes. This improvement was driven by a better emotional state and motivation [18], indicating significant cognitive and emotional benefits even in severe neurodegenerative diseases.
What are the neuroprotective effects of Semax?
Semax protects nerve cells from damage, slows the progression of neurological injuries, and supports regeneration after they occur. Its neuroprotective action is achieved through multiple converging mechanisms.
These include: suppression of neuroinflammation, reduction of oxidative stress, increase in neurotrophic factors, prevention of excitotoxic calcium overload, modulation of vascular gene expression, and correction of ischemia-induced gene expression disorders.
These mechanisms have been documented in numerous injury models — cerebral ischemia, spinal cord injury, photothrombotic stroke, MPTP-induced dopaminergic lesions, and glutamate toxicity. This makes Semax one of the most mechanistically versatile synthetic neuroprotective peptides investigated in preclinical literature. Clinical evidence of neuroprotection in humans comes primarily from studies of ischemic stroke, showing accelerated neurological recovery and reduced lesion volume.
Does Semax reduce neuroinflammation?
Semax significantly reduces neuroinflammation – inflammation within the brain – by acting at the level of gene expression. Genome-wide studies provide extensive evidence for its anti-inflammatory effects.
In a rat stroke model, where the cerebral artery was temporarily blocked and then reopened, simulating human ischaemic stroke, Semax suppressed the activity of inflammatory genes abnormally switched on by the stroke, while reactivating neurochemical transmission-related genes that the stroke had switched off [19]. This constitutes a broad correction of stroke-induced gene expression dysregulation.
Detailed analysis confirmed that Semax significantly reduced the mRNA levels of several key pro-inflammatory signalling proteins: IL-1α, IL-1β, IL-6, CCL3, and CXCL2 [20]. These proteins, when overproduced, drive harmful inflammation in damaged brain tissue.
At the protein level, Semax reduced the concentrations of MMP-9 and c-Fos – proteins linked to inflammation and cellular stress – in the cerebral cortex adjacent to the stroke area. It also reduced the activity of JNK – an enzyme that drives inflammatory cell death – in both cortical and subcortical tissues. Concurrently, it increased the activity of CREB – a key molecular switch responsible for transforming synaptic activity into long-term memory storage – in subcortical structures, including within the stroke zone itself [21]. This pattern of reduced inflammatory signalling alongside increased cell survival signalling is precisely consistent with neuroprotective regeneration.
A genome-wide analysis confirmed that the immune response was the biological process most significantly altered by Semax. Over 50% of all genes responding to Semax within 24 hours of a stroke were immune response genes [23]. In human patients with ischaemic stroke, Semax shifted the balance of immune mediators towards anti-inflammatory factors — it increased interleukin-10 and reduced IL-8 and C-reactive protein [24].
Does Semax reduce oxidative stress?
Semax reduces oxidative stress through several mechanisms, with evidence from cell cultures and live animal studies. Oxidative stress is cell damage caused by free radicals – unstable molecules that, during stroke, injury, or disease, attack cell membranes, proteins, and DNA, contributing to neuron death.
In models of cerebral ischaemia, Semax at a dose of 0.3 mg/kg prevented the excessive production of nitric oxide—a compound which, in excessive amounts, forms highly damaging derivatives that destroy nerve cells—and lowered elevated lipid peroxidation indices in the rat cerebral cortex after the occlusion of both carotid arteries [25].
In the spinal cord injury model, Semax reduced oxidative stress and inhibited pyroptosis, a specific type of inflammatory cell death induced by lysosomal rupture. These effects were mediated by a pathway involving the μ-opioid receptor and the proteins USP18 and FTO [26].
In PC12 cells exposed to hydrogen peroxide, Semax dose-dependently reduced the number of cells damaged by oxidative stress [27].
In the context of Alzheimer's disease research, Semax has demonstrated the ability to remove copper ions from copper-beta-amyloid complexes. Beta-amyloid-bound copper catalyses the generation of free radicals. By removing it, Semax reduced free radical production and protected nerve cells from oxidative damage [28].
In animal models, Semax also counteracted memory impairment induced by toxic heavy metals, achieving efficacy comparable to vitamin C [29].
Does Semax improve cerebral blood flow?
Semax improves cerebral blood flow and vascular function by modulating the expression of vascular genes and reducing vascular stasis—abnormal slowing or halting of blood flow in small vessels.
In histological studies of rat brain ischaemia, Semax reduced signs of ischaemic vascular stasis, which the PGP fragment alone did not reduce. This suggests that the ACTH-derived fragment of Semax provides additional vascular protection [30].
Whole-genome transcriptome analysis identified 24 vascular system-related genes with altered expression influenced by Semax 3 hours after stroke. These included genes controlling endothelial cell development, smooth muscle cell migration, blood cell production, and neovascularisation [23]. After 24 hours, 12 vascular genes remained differentially expressed, indicating sustained regulation of vascular function throughout the critical post-stroke period [23].
Semax's vascular action is also linked to the regulation of the VEGF gene family – proteins that control the formation and permeability of blood vessels. In a model of permanent stroke, Semax affected the expression of VEGF-b and VEGF-d genes, with the most pronounced activation occurring 3 hours after occlusion [31]. The early reduction of VEGF-a in a global ischaemia model is interpreted as a protective effect – reducing abnormal brain swelling in the acute phase of stroke, while maintaining the later beneficial VEGF response that supports tissue repair [32].
Semax also improved red blood cell deformability — their ability to change shape and flow through narrow capillaries — in both healthy and stroke-affected rats [33], which directly improves oxygen delivery to brain tissue.
In the microcirculation model, Semax prevented severe blood flow disorders induced by immobilisation stress when administered an hour beforehand [34], demonstrating that its vascular protection extends to microcirculatory systems beyond the brain.
In a clinical study of 187 patients with cerebrovascular insufficiency, treatment with Semax reduced the risk of stroke, stabilised disease progression, and showed significant clinical improvement [11].
How does Semax protect neurons from excitotoxicity?
Semax protects neurons from excitotoxic death by delaying calcium overload and preserving mitochondrial function. Excitotoxicity occurs when neurons are excessively stimulated by an excess of glutamate – the brain's primary excitatory neurotransmitter. During a stroke, dying cells release large amounts of glutamate, which hyperactivates neighbouring neurons, causing an influx of calcium ions into them. This overload destroys mitochondria and kills the cell. This reaction is one of the main mechanisms by which the primary stroke expands into surrounding healthy tissue.
In cultured cerebellar granule cells exposed to glutamate toxicity, Semax at a concentration of 100 micromoles and its Pro-Gly-Pro delayed the onset of calcium overload and the decline in mitochondrial membrane potential — a key indicator of mitochondrial health — thereby improving neuronal survival by approximately 30% [35].
The protective mechanism involves strengthening mitochondrial resistance to calcium overload, rather than directly blocking glutamate receptors, as confirmed by the finding that Semax did not significantly affect calcium influx through acid-sensitive ion channels [36]. This mitochondrion-focused protection is particularly important for ischaemic neuroprotection, where secondary neuronal death in the penumbra is largely driven by a calcium overload cascade.
Does Semax demonstrate neuroprotective effects in Parkinson's and Alzheimer's disease models?
Semax demonstrates neuroprotective effects in models of both diseases. All these findings are, however, exclusively preclinical—they come from studies on animals or cell cultures, not from clinical trials on humans.
In MPTP-induced Parkinson's disease models — a neurotoxin that destroys dopaminergic cells — daily intranasal administration of Semax at a dose of 0.2 mg/kg reduced the severity of behavioural disorders, including reduced motor activity and increased anxiety-like behaviours. The protective effects were attributed to the modulation of the dopaminergic system and neurotrophic action [37]. In a related model, Semax increased striatal dopamine concentrations when administered before MPTP. Researchers concluded that Semax acts primarily by stimulating the brain's own production of neurotrophic factors rather than acting as a direct antioxidant [38].
In Alzheimer's disease models, Semax inhibited copper-induced beta-amyloid aggregation [39], reduced free radical production by removing copper from copper-beta-amyloid complexes [28], and in transgenic mice with Alzheimer's pathology, it improved cognitive functions and reduced the number of amyloid plaques in the cortex and hippocampus [40]. No clinical studies on humans with Alzheimer's disease patients have been published to date.
What is the general profile of neuroprotective evidence?
Neuroprotective evidence for Semax is extensive at the preclinical level and significantly supported clinically for ischaemic stroke. The convergence of multiple protective mechanisms—anti-inflammatory gene regulation, antioxidant activity, BDNF and NGF outgrowth, vascular gene regulation, mitochondrial protection, and calcium management—creates a multi-layered neuroprotective profile simultaneously addressing several injury mechanisms active in both acute and chronic neurological conditions.
Human clinical evidence, although limited in scale and largely derived from Russian clinical practice, has consistently confirmed the clinical relevance of preclinical findings for ischaemic stroke, cerebrovascular insufficiency, and optic nerve diseases. Well-designed, large-scale, placebo-controlled clinical trials conducted within Western regulatory contexts would significantly strengthen the evidence base.
Disclaimer
This article is for educational and informational-scientific purposes only and should not be interpreted as medical advice, diagnosis, therapeutic recommendation, or a claim regarding the efficacy of Semax in treating any condition. Semax remains a research compound in most countries, including the United States and most European countries, and is not approved by the Food and Drug Administration (FDA) or the European Medicines Agency (EMA) for the treatment of any medical condition. It is approved and used clinically in Russia and some Eastern European countries. Most of the evidence presented in this article comes from preclinical animal studies and a limited number of human clinical trials. Additional, well-designed clinical trials are necessary to more accurately establish the safety, efficacy, mechanisms of action, and long-term effects of Semax in humans.
References
[1] Manchenko, D. M., Glazova, N. Yu., Levitskaia, N. G., Andreeva, L. A., Kamenskiĭ, A. A., & Miasoedov, N. F. (2010). Nootropic and analgesic effects of Semax following different routes of administration. I.M. Sechenov Russian Journal of Physiology, 96(10), 1014–1023. PMID: 21268834
Silachev, D. N., Shram, S. I., Shakova, F. M., Romanova, G. A., & Myasoedov, N. F. (2009). Formation of spatial memory in rats with ischemic lesions to the prefrontal cortex; effects of a synthetic analog of ACTH(4-7). Neuroscience and Behavioral Physiology, 39(8), 749–756. https://doi.org/10.1007/s11055-009-9197-4
[3] Romanova, G. A., Silachev, D. N., Shakova, F. M., Kvashennikova, Yu. N., Viktorov, I. V., Shram, S. I., & Myasoedov, N. F. (2006). Neuroprotective and antiamnesic effects of Semax during experimental ischemic infarction of the cerebral cortex. Bulletin of Experimental Biology and Medicine, 142(6), 663-666. https://doi.org/10.1007/s10517-006-0445-0
[4] Iasnetsov, V. V., & Ivanov, Yu. V. (2004). Pharmacological correction of memory impairment caused by a complex extremal action in mice with bilateral ligation of common carotid arteries. Experimental and Clinical Pharmacology, 67(5), 3–4. PMID: 15559625
[5] Iasnetsov, V. V., Chertorizhskiĭ, E. A., Belyĭ, P. A., Bespalova, Zh. D., Ovchinnikov, M. V., Vereshchagina, A. O., Ivanov, Yu. V., Iasnetsov, Vik. V., Kirsanova, S. K., & Motin, V. G. (2015). Study of neuroprotective, antihypoxic and antiamnesic effects of a new mixture of tripeptides. Experimental and Clinical Pharmacology, 78(1), 3–8. PMID: 25826866
[6] Ashmarin, I. P., Nezavibat’ko, V. N., Miasoedov, N. F., Kamenskiĭ, A. A., Grivennikov, I. A., Ponomareva-Stepnaia, M. A., Andreeva, L. A., Kaplan, A. Ia., Koshelev, V. B., & Riasina, T. V. (1997). A nootropic adrenocorticotropin analogue 4-10-semax (15 years experience in its design and study). Journal of Higher Nervous Activity named after I. P. Pavlov, 47(2), 420–430. PMID: 9173745
[7] Inozemtsev, A. N., Agapitova, A. E., Bokieva, S. B., Glazova, N. Yu., Levitskaia, N. G., Kamenskiĭ, A. A., & Miasoedov, N. F. (2013). Opposite Semax influence on conditioning and functional disturbances of avoidance responses in rats. Journal of Higher Nervous Activity named after I.P. Pavlov, 63(6), 711–718. https://doi.org/10.7868/s0044467713060063
[8] Lebedeva, I. S., Panikratova, Ya. R., Sokolov, O. Yu., Kupriyanov, D. A., Rumshiskaya, A. D., Kost, N. V., & Myasoedov, N. F. (2018). Effects of Semax on the default mode network of the brain. Bulletin of Experimental Biology and Medicine, 165(5), 653–656. https://doi.org/10.1007/s10517-018-4234-3
[9] Eremin, K. O., Kudrin, V. S., Saransaari, P., Oja, S. S., Grivennikov, I. A., Myasoedov, N. F., & Rayevsky, K. S. (2005). Semax, an ACTH(4-10) analogue with nootropic properties, activates dopaminergic and serotoninergic brain systems in rodents. Neurochemical Research, 30(12), 1493–1500. https://doi.org/10.1007/s11064-005-8826-8
[10] Tsai, S. J. (2007). Semax, an analogue of adrenocorticotropin (4-10), is a potential agent for the treatment of attention-deficit hyperactivity disorder and Rett syndrome. Medical Hypotheses, 68(5), 1144–1146. https://doi.org/10.1016/j.mehy.2006.07.017
[11] Gusev, E. I., Skvortsova, V. I., & Chukanova, E. I. (2005). Semax in prevention of disease progress and development of exacerbations in patients with cerebrovascular insufficiency. Journal of Neurology and Psychiatry named after S.S. Korsakov, 105(2), 35–40. PMID: 15792140
[12] Yasenyavskaya, A. L., Samotrueva, M. A., Tsibizova, A. A., Bashkina, O. A., Myasoedov, N. F., & Andreeva, L. A. (2021). The influence of Selank on the level of cytokines under the conditions of „social” stress. Current Reviews in Clinical and Experimental Pharmacology, 16(2), 162-167. https://doi.org/10.2174/1574884715666200704152810
[13] Inozemtseva, L. S., Yatsenko, K. A., Glazova, N. Yu., Kamensky, A. A., Myasoedov, N. F., Levitskaya, N. G., Grivennikov, I. A., & Dolotov, O. V. (2024). Antidepressant-like and antistress effects of the ACTH(4-10) synthetic analogues Semax and Melanotan II on male rats in a model of chronic unpredictable stress. European Journal of Pharmacology, 984, 177068. https://doi.org/10.1016/j.ejphar.2024.177068
[14] Firstova, Yu. Yu., Dolotov, O. V., Kondrakhin, E. A., Dubynina, E. V., Grivennikov, I. A., & Kovalev, G. I. (2009). Effects of nootropic drugs on hippocampal and cortical BDNF levels in mice with different exploratory behaviour efficacy. Experimental and Clinical Pharmacology, 72(6), 3–6. PMID: 20095391
[15] Vanhee, C., Francotte, A., Janvier, S., & Deconinck, E. (2020). The occurrence of putative cognitive enhancing research peptides in seized pharmaceutical preparations: An incentive for controlling agencies to prepare for future encounters of the kind. Drug Testing and Analysis, 12(3), 371–381. https://doi.org/10.1002/dta.2717
[16] Gusev, E. I., Skvortsova, V. I., Miasoedov, N. F., Nezavibat’ko, V. N., Zhuravleva, E. Yu., & Vanichkin, A. V. (1997). Effectiveness of semax in the acute period of hemispheric ischaemic stroke (a clinical and electrophysiological study). Journal of Neurology and Psychiatry named after S.S. Korsakov, 97(6), 26–34. PMID: 11517472
[17] Gusev, E. I., Martynov, M. Yu., Kostenko, E. V., Petrova, L. V., & Bobyreva, S. N. (2018). The efficacy of semax in the treatment of patients at different stages of ischaemic stroke. Journal of Neurology and Psychiatry named after S.S. Korsakov, 118(3), 61–68. https://doi.org/10.17116/jnevro20181183261-68
[18] Serdiuk, A. V., Levitskiĭ, G. N., Miasoedov, N. F., & Skvortsova, V. I. (2007). The study of chronic partial denervation and quality of life in patients with motor neuron disease treated with semax. Journal of Neurology and Psychiatry named after S.S. Korsakov, 107(4), 29–39. PMID: 18379501
[19] Filippenkov, I. B., Stavchansky, V. V., Denisova, A. E., Yuzhakov, V. V., Sevan’kaeva, L. E., Sudarkina, O. Yu., Dmitrieva, V. G., Gubsky, L. V., Myasoedov, N. F., Limborska, S. A., & Dergunova, L. V. (2020). Novel insights into the protective properties of ACTH(4-7)PGP (Semax) peptide at the transcriptome level following cerebral ischaemia-reperfusion in rats. Genes, 11(6), 681. https://doi.org/10.3390/genes11060681
[20] Dergunova, L. V., Dmitrieva, V. G., Filippenkov, I. B., Stavchansky, V. V., Denisova, A. E., Yuzhakov, V. V., Sevan’kaeva, L. E., Valieva, L. V., Sudarkina, O. Yu., Gubsky, L. V., Myasoedov, N. F., & Limborska, S. A. (2021). The peptide drug ACTH(4-7)PGP (Semax) suppresses mRNA transcripts encoding proinflammatory mediators induced by reversible ischaemia of the rat brain. Molecular Biology, 55(3), 402–411. https://doi.org/10.31857/S0026898421010043
[21] Sudarkina, O. Yu., Filippenkov, I. B., Stavchansky, V. V., Denisova, A. E., Yuzhakov, V. V., Sevan’kaeva, L. E., Valieva, L. V., Remizova, J. A., Dmitrieva, V. G., Gubsky, L. V., Myasoedov, N. F., Limborska, S. A., & Dergunova, L. V. (2021). Brain protein expression profile confirms the protective effect of the ACTH(4-7)PGP peptide (Semax) in a rat model of cerebral ischaemia-reperfusion. International Journal of Molecular Sciences, 22(12), 6179. https://doi.org/10.3390/ijms22126179
Medvedeva, E. V., Dmitrieva, V. G., Limborska, S. A., Myasoedov, N. F., & Dergunova, L. V. (2017). Semax, an analogue of ACTH(4-7), regulates expression of immune response genes during ischaemic brain injury in rats. Molecular Genetics and Genomics, 292(3), 635–653. https://doi.org/10.1007/s00438-017-1297-1
[23] Medvedeva, E. V., Dmitrieva, V. G., Povarova, O. V., Limborska, S. A., Skvortsova, V. I., Myasoedov, N. F., & Dergunova, L. V. (2014). The peptide semax affects the expression of genes related to the immune and vascular systems in rat brain focal ischaemia: genome-wide transcriptional analysis. BMC Genomics, 15, 228. https://doi.org/10.1186/1471-2164-15-228
[24] Miasoedova, N. F., Skvortsova, V. I., Nasonov, E. L., Zhuravleva, E. Yu., Grivennikov, I. A., Arsen’eva, E. L., & Sukhanov, I. I. (1999). Investigation of mechanisms of the neuro-protective effect of Semax in the acute period of ischemic stroke. Journal of Neurology and Psychiatry named after S.S. Korsakov, 99(5), 15–19. PMID: 10358912
[25] Bashkatova, V. G., Koshelev, V. B., Fadyukova, O. E., Alexeev, A. A., Vanin, A. F., Rayevsky, K. S., Ashmarin, I. P., & Armstrong, D. M. (2001). A novel synthetic analogue of ACTH 4-10 (Semax) but not glycine prevents the enhanced nitric oxide generation in the cerebral cortex of rats with incomplete global ischaemia. Brain Research, 894(1), 145–149. https://doi.org/10.1016/s0006-8993(00)03324-2
[26] Liu, R., Chen, Y., Huang, H., Li, X., Lv, J., Jiang, L., Jiang, H., Wu, C., Chen, W., Xu, H., Zhu, Z., Cai, H., Xiao, J., Yin, L., & Ni, W. (2025). Semax peptide targets the μ opioid receptor gene Oprm1 to promote deubiquitination and functional recovery after spinal cord injury in female mice. British Journal of Pharmacology, 182(22), 5489–5516. https://doi.org/10.1111/bph.70122
[27] Safarova, E. R., Shram, S. I., Zolotarev, Yu. A., & Myasoedov, N. F. (2003). Effect of Semax peptide on survival of cultured rat pheochromocytoma cells during oxidative stress. Bulletin of Experimental Biology and Medicine, 135(3), 268–271. https://doi.org/10.1023/a:1024141232307
[28] Tomasello, M. F., Di Rosa, M. C., Naletova, I., Sciacca, M. F. M., Giuffrida, A., Maccarrone, G., & Attanasio, F. (2025). Semax, a copper chelator peptide, decreases the Cu(II)-catalysed ROS production and cytotoxicity of Aβ by metal ion stripping and redox silencing. Bioinorganic Chemistry and Applications, 2025, 4226220. https://doi.org/10.1155/bca/4226220
[29] Inozemtsev, A. N., Bokieva, S. B., Karpukhina, O. V., Gumargalieva, K. Z., Kamensky, A. A., & Myasoedov, N. F. (2016). Semax prevents learning and memory inhibition by heavy metals. Doklady Biological Sciences, 468(1), 112–114. https://doi.org/10.1134/S0012496616030066
[30] Stavchansky, V. V., Yuzhakov, V. V., Botsina, A. Yu., Skvortsova, V. I., Bondurko, L. N., Tsyganova, M. G., Limborska, S. A., Myasoedov, N. F., & Dergunova, L. V. (2011). The effect of Semax and its C-end peptide PGP on the morphology and proliferative activity of rat brain cells during experimental ischaemia: A pilot study. Journal of Molecular Neuroscience, 45(2), 177–185. https://doi.org/10.1007/s12031-010-9421-2
[31] Medvedeva, E. V., Dmitrieva, V. G., Povarova, O. V., Limborska, S. A., Skvortsova, V. I., Myasoedov, N. F., & Dergunova, L. V. (2013). Effect of semax and its C-terminal fragment Pro-Gly-Pro on the expression of VEGF family genes and their receptors in experimental focal cerebral ischaemia in rats. Journal of Molecular Neuroscience, 49(2), 328–333. https://doi.org/10.1007/s12031-012-9853-y
[32] Stavchanskiĭ, V. V., Tvorogova, T. V., Botsina, A. Yu., Limborskaia, S. A., Skvortsova, V. I., Miasoedov, N. F., & Dergunova, L. V. (2013). The effect of semax and its C-end peptide PGP on Vegfa gene expression in the rat brain during incomplete global ischaemia. Molecular Biology, 47(3), 461–466. https://doi.org/10.7868/s0026898413030166
[33] Fadyukova, O. E., Tyurina, A. Yu., Lugovtsov, A. E., Priezzhev, A. V., Andreeva, L. A., Koshelev, V. B., & Myasoedov, N. F. (2011). Semax increases erythrocyte deformability in the shearing blood stream in intact rats and rats with cerebral ischaemia. Doklady Biological Sciences, 439, 208–211. https://doi.org/10.1134/S0012496611040168
[34] Kopylova, G. N., Smirnova, E. A., Sanzhieva, L. Ts., Umarova, B. A., Lelekova, T. V., & Samonina, G. E. (2003). Glyprolines and semax prevent stress-induced microcirculatory disturbances in the mesentery. Bulletin of Experimental Biology and Medicine, 136(5), 441–443. https://doi.org/10.1023/b:bebm.0000017087.90585.a9
Storozhevykh, T. P., Tukhbatova, G. R., Senilova, Ya. E., Pinelis, V. G., Andreeva, L. A., & Myasoyedov, N. F. (2007). Effects of semax and its Pro-Gly-Pro fragment on calcium homeostasis of neurons and their survival under conditions of glutamate toxicity. Bulletin of Experimental Biology and Medicine, 143(5), 601–604. https://doi.org/10.1007/s10517-007-0192-x
[36] Kolbaev, S. N., Sharonova, I. N., & Skrebitsky, V. G. (2025). The effect of peptide Semax, an ACTH(4-10) analogue, on intracellular calcium dynamics in rat brain neurons. Bulletin of Experimental Biology and Medicine, 179(4), 416–420. https://doi.org/10.1007/s10517-025-06501-z
[37] Levitskaya, N. G., Sebentsova, E. A., Andreeva, L. A., Alfeeva, L. Yu., Kamenskii, A. A., & Myasoedov, N. F. (2004). The neuroprotective effects of Semax in conditions of MPTP-induced lesions of the brain dopaminergic system. Neuroscience and Behavioural Physiology, 34(4), 399–405. https://doi.org/10.1023/b:neab.0000018752.59465.28
[38] Kolacheva, A. A., & Ugrumov, M. V. (2021). A mouse model of nigrostriatal dopaminergic axonal degeneration as a tool for testing neuroprotectors. Acta Naturae, 13(3), 110–113. https://doi.org/10.32607/actanaturae.11433
[39] Sciacca, M. F. M., Naletova, I., Giuffrida, M. L., & Attanasio, F. (2022). Semax, a synthetic regulatory peptide, affects copper-induced Abeta aggregation and amyloid formation in artificial membrane models. ACS Chemical Neuroscience, 13(4), 486–496. https://doi.org/10.1021/acschemneuro.1c00707
[40] Radchenko, A. I., Kuzubova, E. V., Apostol, A. A., Mitkevich, V. A., Andreeva, L. A., Limborska, S. A., Stepenko, Yu. V., Shmigerova, V. S., Solin, A. V., Korokin, M. V., Pokrovskii, M. V., Myasoedov, N. F., & Makarov, A. A. (2025). The potential of the peptide drug Semax and its derivative for correcting pathological impairments in the animal model of Alzheimer’s disease. Acta Naturae, 17(4), 110–120. https://doi.org/10.32607/actanaturae.27808